William Blair Sees An End To Sarepta's Regulatory Saga, Upgrades And Lifts Price Target To $88

By: via Benzinga
Following Sarepta Therapeutics Inc. (NASDAQ: SRPT) receiving the U.S. Food And Drug Administration's accelerated approval for ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.